Rheumatology Billing Guide 2026

Infusion Coding, Biologic Injections, and E/M Complexity

By Yagnesh Dave  ·  June 2026  ·  15 min read

Rheumatology billing is uniquely complex because it combines high-complexity E/M visits, procedure-heavy infusion suites, costly biologic medications requiring exact J-code reporting, and some of the most demanding prior authorization processes in outpatient medicine. A single infusion visit for a biologic therapy can carry thousands of dollars in drug cost alone, so accurate coding and authorization management matter to the practice's bottom line.

What Is Buy-and-Bill for a Rheumatology Practice?

In buy-and-bill, the practice buys the biologic, administers it in the office and bills the payer for both the drug (a J-code or Q-code, per its descriptor unit) and the administration (96365 and related codes). Your margin is the payer's drug payment minus your acquisition cost, so exact units, group purchasing and waste control matter.

How to Manage Prior Authorization for Buy-and-Bill Biologics

Get authorization for the specific drug, dose and dates before the infusion is scheduled, and log its expiry date and units. Document prior DMARD trials, current disease activity scores and the matching ICD-10 code. Ask for renewal four to six weeks before expiry, and never infuse on a verbal approval.

1. Infusion Coding: The Most Misunderstood Revenue Category in Rheumatology

Therapeutic infusions are billed using a time-based coding system that most practices consistently undercode. The correct billing approach requires accurate documentation of infusion start and stop times and proper application of initial vs. sequential vs. concurrent infusion rules.

The 30-Minute Rule for Add-On Hours

Code 96366 (each additional hour) may be billed for each additional hour, but only if the additional time exceeds 30 minutes. A 1-hour 25-minute infusion bills as 96365 only. A 1-hour 35-minute infusion bills as 96365 + one unit of 96366. This rule is consistently misapplied, leading to either undercoding (lost revenue) or overcoding (audit risk).

Documenting Infusion Time Correctly

Infusion time documentation must include:

• Start time and stop time for each drug infused
• Name of the drug and dose administered
• Route of administration
• Any infusion reactions or nursing interventions
• Pre-medications administered (separately billable if IV)

Nursing flow sheets or electronic infusion records are the gold standard. Hand-written start/stop times on a paper superbill are vulnerable to audit challenge, invest in structured infusion documentation.

2. Biologic Medication J-Codes: Getting Units Right

Every biologic drug administered in the rheumatology office must be reported with the correct HCPCS J-code and the exact number of units. Units are defined per the J-code descriptor, not per dose or per vial. Billing the wrong unit count is one of the most common and costly errors in rheumatology billing.

Biosimilar Billing

Biosimilar versions of rheumatology biologics carry their own HCPCS codes. For infliximab, the biosimilars use Q-codes (Q5103 Inflectra, Q5104 Renflexis, Q5121 Avsola, each per 10 mg), separate from the reference product's J1745. Billing the reference product J-code when a biosimilar was administered, or vice versa, is a compliance risk and a common audit trigger. Always verify the specific product administered against the correct J-code before claim submission.

3. Prior Authorization for Biologics: A Dedicated Workflow Requirement

Virtually every commercial payer and most Medicare Advantage plans require prior authorization for biologic therapies. The authorization process for rheumatology biologics is more complex than most specialties for three reasons: step therapy requirements, clinical criteria thresholds, and peer-to-peer appeal rates.

Step Therapy: The Primary Authorization Barrier

Most commercial payers require patients to fail two or more conventional DMARDs (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide) before approving a biologic. Documentation requirements:

• Documentation of prior DMARD trials, drug name, dose, duration, and reason for discontinuation
• Current disease activity scores (DAS28, CDAI, SDAI for RA; BASDAI for ankylosing spondylitis)
• Recent lab results (CBC, CMP, hepatitis B/C screening where required)
• X-ray or imaging evidence of disease progression (required by some payers)
• ICD-10 diagnosis codes that match the approved biologic indication exactly

Authorization Timeframes and Renewal

Critical rule: Never administer a biologic therapy without confirmed authorization in hand. A denied biologic infusion claim costs far more than delaying treatment by one appointment cycle to secure authorization. Establish a policy that biologic administration requires printed authorization confirmation, not verbal approval.

4. E/M Coding for Rheumatology: Capturing Complexity

Rheumatology visits are routinely high-complexity E/M encounters, but many practices underbill at 99213 or 99214 when the documentation and medical decision-making support 99215. Since 2021, office E/M levels are chosen by medical decision-making (MDM) or total time on the date of the visit, whichever you document better, and many rheumatology visits support 99214 or 99215.

MDM Elements That Can Support 99214 or 99215 in Rheumatology

• Prescription drug management for a biologic or DMARD is moderate risk. Drug therapy requiring intensive monitoring for toxicity can support high risk, but only when labs or other tests are ordered and reviewed to check for toxicity (not efficacy) and long-term monitoring happens at least quarterly
• A chronic illness with exacerbation or progression, such as RA with worsening joint involvement, is a moderate-complexity problem. A severe exacerbation, a new systemic manifestation or serious medication toxicity can reach high
• Reviewing and interpreting labs (CBC, CMP, anti-CCP, ANA panel, imaging) counts toward the data element, and enough qualifying items can reach the extensive level
• An undiagnosed new problem with uncertain prognosis, such as new inflammatory arthritis or suspected connective tissue disease, is moderate complexity and usually comes with a workup that adds to the data element

Same-Day Infusion + E/M Billing

Billing an E/M visit on the same day as an infusion is allowed, but requires a separately identifiable, medically necessary service beyond the infusion supervision itself. The E/M must be distinct from the infusion administration and documented as such. Append modifier 25 to the E/M code. Most rheumatology practices that provide infusions also conduct a clinical assessment; this is separately billable in the majority of visits when documented correctly.

5. Common Rheumatology Denial Patterns and Prevention

6. In-Office Infusion Suite vs. Hospital Outpatient: The Buy-and-Bill Model

The in-office buy-and-bill model, where the rheumatology practice purchases the biologic directly, administers it, and bills both the drug (J-code) and the administration (96365+); is more financially advantageous for most practices than referring patients to a hospital infusion center. Key considerations:

• GPO membership: Joining a Group Purchasing Organization (GPO) significantly reduces drug acquisition cost, improving the margin between purchase price and reimbursement
• 340B programs: Eligible practices (FQHC, certain safety-net providers) can access 340B pricing, dramatically improving biologic margins
• Payer site-of-care policies: Some payers are implementing site-of-care programs that require patients to receive infusions at lower-cost settings. Know your payer contracts and appeal these policies when they conflict with clinical appropriateness
• Inventory management: Biologic wastage due to unused vial portions is a material cost. Proper weight-based dosing documentation and vial-sharing protocols (where permitted) reduce waste

Rheumatology Audit Exposure: Biologic Units, Authorizations, and Step Therapy

Biologic infusions are expensive enough that reviewers read them line by line. They compare the drug billed to the drug ordered and administered, check the units against the J-code descriptor, and confirm the authorization matches the drug, dose, and dates. If an authorization expired or covered a different biologic, the claim can be denied even when the clinical care was correct.

Step therapy documentation is the other place gaps show up. When a payer requires a trial of an earlier drug first, the record has to show which drug, for how long, and the outcome. Contractors can look back three years, and because one regimen is repeated for months, a units error or a missing authorization multiplies with every infusion. Keep an authorization log with expiry dates and check it before each visit.

Frequently Asked Questions About Rheumatology

What is buy-and-bill for a rheumatology practice?

In buy-and-bill, the practice buys the biologic, administers it in the office and bills the payer for both the drug (a J-code or Q-code, per its descriptor unit) and the administration (96365 and related codes). Your margin is the payer's drug payment minus your acquisition cost, so exact units, group purchasing and waste control matter.

How do you manage prior authorization for buy-and-bill biologics?

Get authorization for the specific drug, dose and dates before the infusion is scheduled, and log its expiry date and units. Document prior DMARD trials, current disease activity scores and the matching ICD-10 code. Ask for renewal four to six weeks before expiry, and never infuse on a verbal approval.

Which code do you bill for an infliximab biosimilar?

Infliximab biosimilars use their own Q-codes, such as Q5103 for Inflectra, Q5104 for Renflexis and Q5121 for Avsola, each billed per 10 mg. J1745 is the reference product, Remicade. Bill the code for the exact product given, and check each payer's preferred product before you stock it.

How are infusions coded in rheumatology?

The article says infusions use a time-based coding system that most practices undercode. It requires accurate start and stop times and correct application of the add-on and hierarchy rules for each drug.

How do you get J-code units right?

Units are defined by the J-code descriptor, not by the dose or the vial. The article stresses reporting the exact number of units for each biologic, since a wrong conversion means the wrong payment.

Why do biologic claims get denied for authorization?

The usual reasons, according to the article's denial table, are an expired authorization, the wrong drug authorized, or no authorization at all. It recommends an authorization log with expiry tracking and never administering without one.